Log in

NASDAQ:JNCEJounce Therapeutics Stock Price, Forecast & News

$5.68
+0.25 (+4.60 %)
(As of 05/27/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.32
Now: $5.69
$5.77
50-Day Range
$4.52
MA: $4.93
$5.64
52-Week Range
$2.79
Now: $5.69
$10.00
Volume210,645 shs
Average Volume246,116 shs
Market Capitalization$193.57 million
P/E Ratio4.62
Dividend YieldN/A
Beta2.37
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform. It is also developing JTX-4014, a monoclonal antibody that is in Phase I clinical trial for combination therapy; and JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2 that is in the IND-enabling phase. The company has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Read More
Jounce Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.97 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$147.87 million
Cash Flow$1.86 per share
Book Value$4.48 per share

Profitability

Net Income$56.82 million

Miscellaneous

Employees115
Market Cap$193.57 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

How has Jounce Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, JNCE shares have increased by 32.7% and is now trading at $5.68. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Jounce Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating, 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Jounce Therapeutics.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Jounce Therapeutics.

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics Inc (NASDAQ:JNCE) released its earnings results on Wednesday, May, 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.21. Jounce Therapeutics had a net margin of 46.11% and a return on equity of 28.10%. View Jounce Therapeutics' earnings history.

What price target have analysts set for JNCE?

4 brokers have issued twelve-month price targets for Jounce Therapeutics' stock. Their forecasts range from $8.00 to $11.00. On average, they expect Jounce Therapeutics' share price to reach $9.50 in the next year. This suggests a possible upside of 67.3% from the stock's current price. View analysts' price targets for Jounce Therapeutics.

Has Jounce Therapeutics been receiving favorable news coverage?

News coverage about JNCE stock has been trending very negative recently, InfoTrie reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Jounce Therapeutics earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. View the latest news aboutJounce Therapeutics.

Are investors shorting Jounce Therapeutics?

Jounce Therapeutics saw a decrease in short interest in April. As of April 30th, there was short interest totaling 2,000,000 shares, a decrease of 11.9% from the April 15th total of 2,270,000 shares. Based on an average daily volume of 378,700 shares, the short-interest ratio is currently 5.3 days. Approximately 12.3% of the shares of the stock are sold short. View Jounce Therapeutics' Current Options Chain.

Who are some of Jounce Therapeutics' key competitors?

What other stocks do shareholders of Jounce Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), Crispr Therapeutics (CRSP), Progenics Pharmaceuticals (PGNX), Bausch Health Companies (BHC), Exelixis (EXEL), Incyte (INCY), Nektar Therapeutics (NKTR), Omeros (OMER), Sangamo Therapeutics (SGMO) and AT&T (T).

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the following people:
  • Dr. Richard Murray, Pres, CEO & Director (Age 60)
  • Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 54)
  • Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 59)
  • Dr. James P. Allison, Founder
  • Dr. Thomas F. Gajewski, Founder

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.65%), Acadian Asset Management LLC (2.81%), AQR Capital Management LLC (1.83%), State Street Corp (1.23%), Massachusetts Financial Services Co. MA (0.83%) and Granahan Investment Management Inc. MA (0.78%). Company insiders that own Jounce Therapeutics stock include Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View institutional ownership trends for Jounce Therapeutics.

Which institutional investors are selling Jounce Therapeutics stock?

JNCE stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Deutsche Bank AG, JPMorgan Chase & Co., Geode Capital Management LLC, Bank of New York Mellon Corp, Systematic Financial Management LP, UBS Group AG, and Morgan Stanley. Company insiders that have sold Jounce Therapeutics company stock in the last year include Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, and Richard /Ca/ Murray. View insider buying and selling activity for Jounce Therapeutics.

Which institutional investors are buying Jounce Therapeutics stock?

JNCE stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Massachusetts Financial Services Co. MA, Acadian Asset Management LLC, Russell Investments Group Ltd., Granahan Investment Management Inc. MA, Congress Asset Management Co. MA, Los Angeles Capital Management & Equity Research Inc., and GSA Capital Partners LLP. View insider buying and selling activity for Jounce Therapeutics.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $5.68.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $193.40 million and generates $147.87 million in revenue each year. The company earns $56.82 million in net income (profit) each year or $1.66 on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.

What is Jounce Therapeutics' official website?

The official website for Jounce Therapeutics is www.jouncetx.com.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.